Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Completed Phase 4 Interventional

Trial of NovoSeven® in Haemophilia - Joint Bleeds

NCT00108797
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated), Feiba VH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 20 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
20
States / cities
Little Rock, Arkansas • Berkeley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

NCT00056589
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

NCT01943084
View directory record Official record
Conditions
Growth Disorder, Healthy
Interventions
Norditropin® FlexPro® pen, Genotropin Pen®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

NCT01664247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01068665
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
62
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 4 Interventional Results available

Liraglutide Effects on Epicardial Fat Inflammatory Genes

NCT03260881
View directory record Official record
Conditions
Type2 Diabetes, Coronary Artery Disease
Interventions
Liraglutide Pen Injector [Victoza], matching liraglutide-placebo pre-filled pens
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 13, 2026, 6:08 PM EDT
Active, not recruiting Phase 3 Interventional

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281
View directory record Official record
Conditions
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Interventions
Ziltivekimab, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
188
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 156 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Active, not recruiting Phase 1 Interventional

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

NCT06577766
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0638-0355, Placebo (NNC0638-0355)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

NCT00108849
View directory record Official record
Conditions
Menopause, Postmenopausal Vaginal Atrophy
Interventions
estradiol, 10 mcg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
51
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional Results available

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional

Improving Glycemic Control on GMS: A Quality Improvement Study

NCT00271700
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Order Set, Education, Feedback
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

NCT05649137
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Montgomery, Alabama • Concord, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

NCT03987451
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

NCT01959529
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
7,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
267
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 13, 2026, 6:08 PM EDT
Withdrawn Phase 4 Interventional

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

NCT00906529
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Levemir (Detemir) and Novolog (Aspart) Insulin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

NCT03015207
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

NCT06874751
View directory record Official record
Conditions
Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
45,456 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

NCT02568202
View directory record Official record
Conditions
Haemostasis, Congenital Bleeding Disorder, Haemophilia B
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

NCT02868229
View directory record Official record
Conditions
Anemia
Interventions
COR-001, Placebo
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Northridge, California • Hollywood, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 13, 2026, 6:08 PM EDT
Not yet recruiting Phase 1 Interventional

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

NCT07868354
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Tirzepatide, Zenagamtide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Active, not recruiting Phase 3 Interventional

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

NCT05669755
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years and older
Enrollment
7,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
119
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

NCT00184548
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 13, 2026, 6:08 PM EDT